Press release
Dengue Fever Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight |Kino Pharma, Abivax, Plex Pharma, Codagenix, Atea Pharma
The Dengue Fever Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Dengue Fever Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dengue Fever Market.
Some of the key takeaways from the Dengue Fever Pipeline Report:
* Companies across the globe are diligently working toward developing novel Dengue Fever treatment therapies with a considerable amount of success over the years.
* Dengue Fever companies working in the treatment market are Kino Pharma, Abivax, Plex Pharmaceuticals, Codagenix, Atea Pharmaceuticals, Emergex Vaccines, Visterra, Janssen Research & Development, Merck & Co., Takeda, and others, are developing therapies for the Dengue Fever treatment
* Emerging Dengue Fever therapies such as - anti-RNA virus therapeutics, ABX220, Infectious diseases therapeutics Programme, CDX DENV, AT-752, LD vehicle-GNP, VIS513, JNJ-64281802, TV003, V 503, and others are expected to have a significant impact on the Dengue Fever market in the coming years.
* In Febuary 2024, The TAK-003 vaccine represents a novel approach to combatting dengue fever in regions heavily impacted by the disease.
Dengue Fever Overview
Dengue fever is a viral infection transmitted primarily by the Aedes mosquito, particularly Aedes aegypti. It is caused by the dengue virus, which belongs to the Flaviviridae family. Dengue fever is prevalent in tropical and subtropical regions, including Southeast Asia, the Pacific Islands, the Caribbean, and parts of Central and South America.
Get a Free Sample PDF Report to know more about Dengue Fever Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/dengue-fever-pipeline-insight [https://www.delveinsight.com/report-store/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Dengue Fever Drugs Under Different Phases of Clinical Development Include:
* Research programme: anti-RNA virus therapeutics - Kino Pharma
* ABX220: Abivax
* Infectious diseases therapeutics Programme: Plex Pharmaceuticals
* CDX DENV: Codagenix
* AT-752: Atea Pharmaceuticals
* LD vehicle-GNP: Emergex Vaccines
* VIS513: Visterra
* JNJ-64281802: Janssen Research & Development
* TV003: Merck & Co.
* V 503: Takeda
Route of Administration
Dengue Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
* Subcutaneous
* Intravenous
* Intramuscular
* Molecule Type
Molecule Type
Products have been categorized under various Molecule types, such as
* Small molecules
* Proteins
* Monoclonal antibodies
* Product Type
Dengue Fever Pipeline Therapeutics Assessment
* Dengue Fever Assessment by Product Type
* Dengue Fever By Stage and Product Type
* Dengue Fever Assessment by Route of Administration
* Dengue Fever By Stage and Route of Administration
* Dengue Fever Assessment by Molecule Type
* Dengue Fever by Stage and Molecule Type
DelveInsight's Dengue Fever Report covers around 10+ products under different phases of clinical development like
* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration
Further Dengue Fever product details are provided in the report. Download the Dengue Fever pipeline report to learn more about the emerging Dengue Fever therapies [https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Dengue Fever Therapeutics Market include:
Key companies developing therapies for Dengue Fever are - Takeda Pharmaceutical Co Ltd, BioNet-Asia Co Ltd, Emergex Vaccines Holding Ltd, Johnson & Johnson, 60 Degrees Pharmaceuticals LLC, and Abivax SA among others.
Dengue Fever Pipeline Analysis:
The Dengue Fever pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Dengue Fever with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dengue Fever Treatment.
* Dengue Fever key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Dengue Fever Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dengue Fever market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Dengue Fever drugs and therapies [https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Dengue Fever Pipeline Market Drivers
* Fastest spreading mosquito-borne viral disease, search of novel tools and innovative strategies to interrupt transmission of dengue, integration of vector management approaches is encouraged are some of the important factors that are fueling the Dengue Fever Market.
Dengue Fever Pipeline Market Barriers
* However, challenging research due to multiple stereotypes, disease risks may change and shift with climate change in tropical and subtropical areas and other factors are creating obstacles in the Dengue Fever Market growth.
Scope of Dengue Fever Pipeline Drug Insight
* Coverage: Global
* Key Dengue Fever Companies: Kino Pharma, Abivax, Plex Pharmaceuticals, Codagenix, Atea Pharmaceuticals, Emergex Vaccines, Visterra, Janssen Research & Development, Merck & Co., Takeda, and others
* Key Dengue Fever Therapies: anti-RNA virus therapeutics, ABX220, Infectious diseases therapeutics Programme, CDX DENV, AT-752, LD vehicle-GNP, VIS513, JNJ-64281802, TV003, V 503, and others
* Dengue Fever Therapeutic Assessment: Dengue Fever current marketed and Dengue Fever emerging therapies
* Dengue Fever Market Dynamics: Dengue Fever market drivers and Dengue Fever market barriers
Request for Sample PDF Report for Dengue Fever Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1
Dengue Fever Report Introduction
2
Dengue Fever Executive Summary
3
Dengue Fever Overview
4
Dengue Fever- Analytical Perspective In-depth Commercial Assessment
5
Dengue Fever Pipeline Therapeutics
6
Dengue Fever Late Stage Products (Phase II/III)
7
Dengue Fever Mid Stage Products (Phase II)
8
Dengue Fever Early Stage Products (Phase I)
9
Dengue Fever Preclinical Stage Products
10
Dengue Fever Therapeutics Assessment
11
Dengue Fever Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Dengue Fever Key Companies
14
Dengue Fever Key Products
15
Dengue Fever Unmet Needs
16
Dengue Fever Market Drivers and Barriers
17
Dengue Fever Future Perspectives and Conclusion
18
Dengue Fever Analyst Views
19
Appendix
20
About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dengue-fever-pipeline-and-clinical-trials-assessment-2024-updates-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-kino-pharma-abivax-plex-pharma-codagenix-atea-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dengue Fever Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight |Kino Pharma, Abivax, Plex Pharma, Codagenix, Atea Pharma here
News-ID: 3453920 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Dengue
Key Trend Reshaping the Dengue Treatment Market in 2025: Innovative Drug Deliver …
Which drivers are expected to have the greatest impact on the over the dengue treatment market's growth?
The escalation in cases of dengue is projected to stimulate the expansion of the market for dengue treatments. Dengue is a viral infection transmitted by mosquito bites, causing symptoms akin to the flu and can escalate to intense complications if not treated. The escalation is primarily due to progressing urbanization, climate alterations favourable to…
Key Dengue Vaccine Market Trend for 2025-2034: Advancements In Dengue Tetravalen …
What Is the Future Outlook for the Dengue Vaccine Market's Size and Growth Rate?
In the past few years, the dengue vaccine market has experienced significant growth. From $0.64 billion in 2024, it is projected to reach $0.72 billion in 2025, marking a compound annual growth rate (CAGR) of 12.4%. This notable expansion during the historical period can be credited to factors such as an increase in travel and urbanization trends,…
Dengue Vaccine Market : An Detailed Overview
Introduction:
Dengue fever is a mosquito-borne viral infection caused by the dengue virus, transmitted primarily through Aedes aegypti and Aedes albopictus mosquitoes. Affecting millions globally each year, dengue has become a significant public health concern, especially in tropical and subtropical regions. The development of dengue vaccines represents a groundbreaking advancement in preventing the disease, reducing its associated healthcare costs, and controlling outbreaks. With increasing awareness and investments in immunization programs, the…
Dengue Vaccine Market : An Overview
Introduction:
Dengue fever is a mosquito-borne viral infection that has become a significant public health challenge in tropical and subtropical regions. The disease is caused by the dengue virus, which is transmitted primarily by Aedes aegypti mosquitoes. With approximately 390 million infections annually, dengue fever places a substantial burden on healthcare systems and economies worldwide. Efforts to mitigate this burden have led to the development of dengue vaccines, designed to prevent…
"Rising Incidence of Dengue Fever Propels Dengue Virus Diagnostic Tests Market T …
According to WHO, dengue affects about 50-100 million people worldwide, annually. It is a vector-borne highly communicable disease. This report discusses the diagnostic tests used to confirm the presence of dengue in one individual.
It is true that the growth of the global dengue virus diagnostic tests market is primarily driven by an increase in the incidence of dengue fever, which is a mosquito-borne viral infection that can cause severe flu-like…
Dengue Vaccines Market 2021 | Detailed Report
Dengue Vaccines Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027.
Get Free Sample PDF (including full TOC, Tables and Figures) of Dengue Vaccines Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4644240
The report provides a comprehensive analysis of company profiles listed below:
- Sanofi
- Takeda
Dengue Vaccines Market Segment by…
